The primary conundrum in treatment and management of early stage estrogen receptor positive (ER+) breast cancer (BCa) is identifying which of these cancers are candidates for adjuvant chemotherapy and which patients will respond to hormonal therapy alone. Here, ESR1 is linked to cancer.